Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases in the United States. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. was founded in 2007 and is headquartered in Yardley, Pennsylvania. Show more

The Tannery Building, Yardley, PA, 19067, United States

Biotechnology

Healthcare

Market Cap

1.113B

52 Wk Range

$3.34 - $7.00

Previous Close

$5.42

Open

$5.34

Volume

1,525,387

Day Range

$5.24 - $5.46

Enterprise Value

994.6M

Cash

173M

Avg Qtr Burn

-29.75M

Insider Ownership

2.59%

Institutional Own.

Qtr Updated

06/30/26

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
MOLBREEVI (Molgramostim) Details Autoimmune Pulmonary Alveolar Proteinosis (aPAP)	PDUFA Approval decision	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.